José Andrés Castro Gamboa

Dr. José Andrés Castro Gamboa

Universidad de Costa Rica, San José, Costa Rica
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JMJeaustin Arón Mora
Jeaustin Arón Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.

6 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
KCKevin Cruz-Mora
Kevin Cruz-Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.

2 November 2026 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
JVJorge Arturo Villalobos-Madriz
Jorge Arturo Villalobos-Madriz
KTKevin Tencio-Morales
Kevin Tencio-Morales
BEBrandon Enríquez-Gutiérrez
Brandon Enríquez-Gutiérrez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
Background/Objectives: Cardiac adverse-event reports for antineoplastic agents may differ across regulatory coding categories, affecting disproportionality estimates. We compared anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted agents, and vascular endothelial growth factor (VEGF) inhibitors. Methods: We analyzed aggregated World Health Organization VigiAccess data retrieved on March 23, 2026, for eight drugs in three classes. Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and cardiac Preferred Term distributions were described; reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated using a restricted antineoplastic comparator cohort. Pairwise within-cohort comparators and cardiac/vascular outcomes were explored; an external database-wide comparison was not feasible. Results: Across 389,068 drug-specific report observations, anti-HER2 agents had the highest proportion classified under Cardiac disorders (10.43%) and the strongest class-level ROR (2.04; 95% CI 1.99–2.10); trastuzumab had the highest drug-level ROR (2.22; 2.16–2.29). Anthracyclines contributed the most cardiac reports (11,273), whereas anti-VEGF agents showed greater proportional reporting in vascular disorders (10.86%) and prominent myocardial infarction reports among cardiac Preferred Terms. Exploratory analyses demonstrated sensitivity to comparator composition and outcome definition. Conclusions: Reporting patterns varied across classes, but these findings do not establish incidence, causality, comparative clinical risk, or independent grounds for changing surveillance protocols.

29 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
JVJorge Arturo Villalobos-Madriz
Jorge Arturo Villalobos-Madriz
KTKevin Tencio-Morales
Kevin Tencio-Morales
BEBrandon Enríquez-Gutiérrez
Brandon Enríquez-Gutiérrez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
Background/Objectives: Antineoplastic therapies have improved cancer survival but remain a major source of treatment-related cardiotoxicity. Previous pharmacovigilance studies have largely focused on drug-specific cardiac signals or individual therapeutic pathways, whereas cross-class differences in cardiovascular reporting across MedDRA categories and their impact on disproportionality estimates remain less well characterized. We therefore compared cardiac adverse-event reporting patterns across anthracyclines, anti-HER2 agents, and anti-VEGF agents within a restricted antineoplastic comparator cohort. Methods: A retrospective pharmacovigilance study was conducted using aggregated ICSR data from VigiBase accessed through the public VigiAccess interface (March 23, 2026). Eight antineoplastic agents were grouped into three therapeutic classes. Descriptive analyses of demographic characteristics, System Organ Class (SOC) distributions, and cardiac Preferred Terms (PT) were performed. Reporting Odds Ratios (ROR) with 95% confidence intervals were calculated using a restricted antineoplastic comparator cohort. Signals were defined as a lower 95% CI bound >1 with at least five cardiac reports. Results: Across eight drug-specific VigiAccess queries, 389,068 drug-specific report observations were analyzed. Anti-HER2 agents showed the highest proportional cardiac-reporting burden (10.43%) and the strongest class-level disproportionality signal (ROR 2.04; 95% CI: 1.99–2.10), with trastuzumab showing the strongest individual-drug estimate (ROR 2.22; 95% CI: 2.16–2.29). Anthracyclines accounted for the largest number of cardiac reports (n = 11,273), with a reporting pattern dominated by myocardial-dysfunction Preferred Terms, led by cardiomyopathy and heart failure. Anti-VEGF agents showed greater reporting within the Vascular disorders (10.86%) and Renal and urinary disorders (6.08%) SOCs, with myocardial infarction among the most frequently reported cardiac PTs. Conclusions: Cardiac adverse event reporting for antineoplastic therapy follows class-specific patterns rather than a uniform profile. Anti-HER2 agents showed the highest proportion of reports classified under Cardiac disorders, anthracyclines the greatest absolute volume, and anti-VEGF therapies exhibited a distinct vascular–ischemic reporting profile. These reporting-based signals may support hypotheses regarding class-specific cardiovascular surveillance consistent with established cardio-oncology guidance, while highlighting both the value and the inherent limitations of global spontaneous-reporting pharmacovigilance data. These findings are hypothesis-generating and should be interpreted as reporting patterns rather than incidence estimates, comparative clinical risks, or causal effects. Spontaneous-reporting data remain susceptible to reporting bias, unmeasured confounding, and incomplete clinical information.

3 October 2026 in Psychoactives
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
KCKevin Cruz-Mora
Kevin Cruz-Mora
RGRicardo Millán González
Ricardo Millán González
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.

17 November 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
LMLuis Carlos Monge-Bogantes
Luis Carlos Monge-Bogantes
AHAndreina Hernandez-Cordonero
Andreina Hernandez-Cordonero
KCKevin Cruz-Mora
Kevin Cruz-Mora
SCSofía Segura Cano
Sofía Segura Cano
JMJeaustin Arón Mora
Jeaustin Arón Mora
Pharmaceutical indication and pharmacist prescribing are distinct mechanisms through which community pharmacists can contribute to primary care, particularly in managing minor symptoms and low-complexity conditions. This narrative review critically compared scientific, regulatory, and institutional sources identified through PubMed/MEDLINE, ScienceDirect, Google Scholar, and consultation of regulatory and professional documents. Domains of the Scale for the Assessment of Narrative Review Articles (SANRA) informed appraisal of the manuscript, rather than source selection or assessment of individual studies. Four recurrent analytical configurations were identified: pharmaceutical indication, protocol-based medicine supply or prescribing, collaborative prescribing, and independent prescribing. Their legal bases, clinical scopes, medicine-access mechanisms, and implementation requirements differ between and within jurisdictions. In the examples reviewed, structured services variously specify eligibility criteria, red-flag assessment, safety-netting, referral, documentation, and coordination with other healthcare professionals. Heterogeneous study designs and outcome measures limit comparisons of clinical effectiveness, safety, service utilization, and costs; no universal hierarchy among regulatory configurations can be established. In selected Latin American settings, including Costa Rica, pharmaceutical consultation and indication are documented, although formalization varies. Future research should prioritize comparable definitions, standardized outcomes, and sustainability.